Another explanation for the phenomenon of pan-resistance lies in the work of Sharma et al. [71], who used an in vitro model of non small cell lung cancer (NSCLC) treated with an EGFR-targeting tyrosine kinase inhibitor to generate drug-tolerant persisters (DTPs) with 100-fold reduced drug sensitivity. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.